A 52-week Open-label (Sponsor-blind), Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Initiating Dialysis
Phase of Trial: Phase III
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Daprodustat (Primary) ; Darbepoetin alfa; Darbepoetin alfa
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms ASCEND-ID
- Sponsors GlaxoSmithKline
- 01 Mar 2018 Planned End Date changed from 15 Nov 2019 to 5 Jun 2020.
- 01 Mar 2018 Planned primary completion date changed from 15 Nov 2019 to 5 Jun 2020.
- 13 Jul 2017 Planned primary completion date changed from 18 Oct 2019 to 15 Nov 2019.